Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St. Jude Medical's Unify and Fortify

This article was originally published in The Gray Sheet

Executive Summary

Firm's Unify cardiac resynchronization therapy defibrillator and Fortify implantable cardioverter defibrillator gain FDA approval, announced May 12. The devices feature 45 Joules of stored energy and can deliver 40 Joules - "the highest energy of any ICD available today," the company claims. The implants also have "the smallest device footprint in the industry and rapid charge times, without any compromise in device longevity," the firm states. Their debut positions St. Jude to gain market share "over the balance of 2010 and well into 2011," states J.P. Morgan analyst Michael Weinstein. Separately, St. Jude announced the European launch of its Promote Quadra CRT-D on May 11. The latter device incorporates the first quadripolar pacing system available, and the four pacing electrodes on the left ventricular lead enable up to 10 pacing configurations, according to the company
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

MT028896

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel